NEW YORK – Chimeric Therapeutics said Tuesday that it has signed an agreement to apply WuXi Advanced Therapies' process and manufacturing capabilities to development of autologous CAR T-cell therapies. Initially, the companies will advance Chimeric's candidate CHM 2101 for gastrointestinal cancers and neuroendocrine tumors and CHM 1101 for glioblastoma.
CHM 1101 and CHM 2101 are made by modifying the patient's own T cells with domains designed to target a specific tumor type.
CHM 1101 carries a peptide derived from scorpion venom to target glioblastoma cells through a membrane-bound metalloprotease 2 receptor (MMP2) complex. It's in a Phase I clinical trial for patients with recurrent or progressive glioblastoma and 20 percent or more expression of CLTX-targeted antigen MMP2.
Philadelphia-based WuXi Advanced Therapies, which is a business unit of WuXi AppTec, will assist Chimeric with scalable manufacturing and analytical testing in preparation for CHM 1101 in order to expand the program to additional clinical trial sites and indications in the future including metastatic melanoma. The product is also covered by a recent partnership with Be The Match BioTherapies, which provides collection, transport, and delivery of cellular starting material and clinical drug product.
CHM 2101 is designed to target CDH17, a cell surface antigen. In normal cells, CDH17 is buried beneath tight junctions and not accessible for binding. However, in cancer cells, CDH17 is upregulated, providing exposure for binding of the CDH17 targeted CAR T cells. WuXi will support this program by providing end-to-end closed-loop CAR T process development and good manufacturing practices (GMP) expertise to prepare the product for a first-in-human study.
Chimeric is also developing a line of off-the-shelf, natural killer cell-derived allogeneic therapies including CHM 0201, which is in a Phase I clinical trial for solid tumors and hematological malignancies, and several other products in preclinical development stages.